Studies found that in colorectal cancer, colony-stimulating factor-1 receptor (CSF1R) inhibitors specifically inhibited the survival of protumor M2 TAMs while having little effect on the growth of anti-tumor M1 TAMs, resulting in an increased M1/M2 ratio [73, 74]. The gene discussed is CSF1R; the disease is neoplasm.